Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ABT 491

Known as: ABT-491 
 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

ImidazolesIndoles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Treatment with a platelet‐activating factor receptor antagonist improves hemodynamics and reduces epinephrine requirements, in a lethal rodent model of anaphylactic shock
In some cases, anaphylactic shock (AS) is still lethal, despite rapid use of epinephrine. High doses of epinephrine are… Expand
2018
2018
Structural basis for signal recognition and transduction by platelet-activating-factor receptor
  • C. Cao, Q. Tan, +19 authors B. Wu
  • Nature Structural & Molecular Biology
  • 2018
    • Corpus ID: 44071735
Platelet-activating-factor receptor (PAFR) responds to platelet-activating factor (PAF), a phospholipid mediator of cell-to-cell… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
2017
2017
Relief from neuropathic pain by blocking of the platelet-activating factor–pain loop
Neuropathic pain resulting from peripheral neuronal damage is largely resistant to treatment with currently available analgesic… Expand
2008
2008
The influence of platelet activating factor on the effects of platelet agonists and antiplatelet agents in vitro
  • F. Keating, David J. Schneider
  • Journal of Thrombosis and Thrombolysis
  • 2008
    • Corpus ID: 6464891
We assessed the effect of the intercellular mediator of inflammation, platelet activating factor (PAF), on platelet function. The… Expand
  • figure 1
  • table 1
  • figure 3
  • figure 2
  • table 2
2007
2007
Platelet-activating factor antagonist (ABT-491) decreases neuronal apoptosis in neonatal rat model of hypoxic ischemic brain injury
Hypoxic ischemic brain injury (HIBI) is a common cause of neonatal mortality and morbidity. To date, no study has investigated… Expand
2006
2006
MCI-186 (edaravone), a free radical scavenger, attenuates ischemia-reperfusion injury and activation of phospholipase A(2) in an isolated rat lung model after 18 h of cold preservation.
OBJECTIVE Increased microvascular permeability and extravasation of inflammatory cells are key events in ischemia-reperfusion (IR… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
1998
1998
The role of platelet-activating factor (PAF) and the efficacy of ABT-491, a highly potent and selective PAF antagonist, in experimental allergic rhinitis.
Platelet-activating factor (PAF) may be an important mediator of allergic rhinitis. In the present study we evaluated the… Expand
  • figure 2
  • figure 3
  • table 1
  • figure 4
  • figure 5
1998
1998
Discovery and evaluation of a series of 3-acylindole imidazopyridine platelet-activating factor antagonists.
Studies conducted with the goal of discovering a second-generation platelet-activating factor (PAF) antagonist have identified a… Expand
1997
1997
Pharmacology of ABT-491, a highly potent platelet-activating factor receptor antagonist.
ABT-491 (4-ethynyl-N, N-dimethyl-3-[3-fluoro-4-[(2-methyl-1H-imidazo-[4,5-c]pyridin-1-yl)methy l]benzoyl]-1H- indole-1… Expand
1997
1997
ABT-491, a highly potent and selective PAF antagonist, inhibits nasal vascular permeability associated with experimental allergic rhinitis in Brown Norway rats
Allergic rhinitis is an inflammatory disease of the upper airway. Symptoms of the disease, which include congestion, rhinorrhea… Expand
  • figure 2
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE